Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.
Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.
With its corporate mission of "caring for life", Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face.
Following its “Vision 2026”, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders.
Fresenius Kabi employs over 40,000 people worldwide. In 2022 the company reported sales of more than €7 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.
Key figures (IFRS)
|€ in milions||2022||2021||Growth|
|7,850||7,193||+ 4 %|
|1,080||1,153||- 14 %|
|13.8 %||16.0 %|
|1,243||533||+ 133 %|
R & D expenses
|629||595||+ 6 %|
Employees (December 31)
|42,063||41,397||+ 2 %|
- Some figures adjusted for special items
- Net income = Net income attributable to shareholders of Fresenius Kabi